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a b s t r a c t
Cell wall mycolic acids (MA) from Mycobacterium tuberculosis (M.tb) are CD1b presented antigens that
can be used to detect antibodies as surrogate markers of active TB, even in HIV coinfected patients. The
use of the complex mixtures of natural MA is complicated by an apparent antibody cross-reactivity with
cholesterol. Here ﬁrstlywe report three recombinantmonoclonal scFv antibody fragments in the chicken
germ-line antibody repertoire, which demonstrate the possibilities for cross-reactivity: the ﬁrst recog-
nized both cholesterol and mycolic acids, the second mycolic acids but not cholesterol, and the third
cholesterol but not mycolic acids. Secondly, MA structure is experimentally interrogated to try to under-
stand the cross-reactivity. Unique synthetic mycolic acids representative of the three main functional
classes show varying antigenicity against human TB patient sera, depending on the functional groups
present and on their stereochemistry. Oxygenated (methoxy- and keto-) mycolic acid was found to be
more antigenic than alpha-mycolic acids. Synthetic methoxy-mycolic acids were the most antigenic, onentigenicity
containing a trans-cyclopropane apparently being somewhat more antigenic than the natural mixture.
Trans-cyclopropane-containing keto- and hydroxy-mycolic acids were also found to be the most anti-
genic among each of these classes. However, none of the individual synthetic mycolic acids signiﬁcantly
and reproducibly distinguished the pooled serumof TB positive patients from that of TB negative patients
better than the naturalmixture ofMA. This argues against the potential to improve the speciﬁcity of sero-
diagnosis of TB with a deﬁned single synthetic mycolic acid antigen from this set, although sensitivity
g a smay be facilitated by usin
. Introduction
South Africa currently has the highest per capita incidence of
B in the world. In 2007 alone 112,000 people died of TB in South
frica, of whom 94,000 were co-infected with HIV (WHO, 2009).
ne of the biggest challenges facing clinicians is the time it takes
o accurately diagnose TB. Currently, using the conventional meth-
ds, it takes on average 4 weeks to diagnose TB, which leads to a
elay in treatment of the disease. Two thirds of TB deaths could
e prevented by early diagnosis. With fast diagnosis patients could
∗ Corresponding author. Tel.: +27 124202477; fax: +27 123625302.
E-mail address: Jan.Verschoor@up.ac.za (J.A. Verschoor).
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be put on anti-TB therapy immediately and become non-infective
within a few days. With the current methods of diagnosis, patients
with persistent symptoms have to remain in quarantine for several
weeks while awaiting the results. During this time, they can infect
themedical staff, their next of kin or anyonewithwhom they share
a closed area, such as in public transport. With MDR and XDR TB
on the increase, this threatens to spread an almost incurable dis-
ease among hospital staff and the communities that can be fatal
within 2 months. The need for a fast, reliable diagnostic tool for
TB is therefore high, especially in high HIV incidence populations
Open access under CC BY license.(Wood, 2007).
Immunodiagnostic assays detecting pathogen related antibod-
ies inpatient serawithactiveTBdiseaseareanattractivealternative
for rapid diagnosis. An array ofmycobacterial cell wall components
have been considered as antigens for surrogate marker antibodies
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or TB (Fujiwara et al., 1999; Lyashcenko et al., 1998; Nabeshima
t al., 2005). Antigenic activity of mycolic acids (MA) and their gly-
olipid derivatives such as the lipid extractable trehalose mono-
r dimycolates, TMM or TDM respectively (cord factors) has been
eviewed recently (Sekanka et al., 2007). Of all the antigens preva-
ent in the cell wall of the mycobacteria that may be considered for
se in TB serodiagnosis, MAs provide a special opportunity due to
heir abundance, variability among different species of Mycobac-
erium and the unique way that they communicate their presence
o the immune response of the host (Sekanka et al., 2007; Shui et
l., 2007; Yuan et al., 1997). The ability of MAs to elicit CD4-, CD8-
ouble negative T cells by means of their presentation on CD1b
roteins of dendritic cells (Beckman et al., 1994) may well be the
eason that antibody binding to MAs in AIDS patients with even
ery low CD4 T cell counts is maintained, relative to other patients
hat are not infected with HIV, or have normal CD4 T cell counts
Schleicher et al., 2002). Pan et al. have shown that the most deter-
ining antigenic part of the cord factor antigen is the MA (Pan et
l., 1999).
The use of MA antigens to detect antibodies as surrogate mark-
rs for TB diagnosis was shown to be feasible in ELISA assays (Pan
t al., 1999; Schleicher et al., 2002), albeit of limited accuracy.
ne complication was the apparent cross-reactivity of TB patient
erum antibodies between MAs and cholesterol, most likely due
o a shared structural feature between cholesterol and a folded
orm of MA, as both could be liganded by Amphotericin B, a choles-
erol binding drug (Benadie et al., 2008). A biosensor approach, the
ARTI-test (Mycolic acids Antibody Real-Time Inhibition), using
ree naturalmixtures ofMAs in liposomes as antigens in a competi-
ive binding assay showed improved accuracy (Lemmer et al., 2009;
hanyani et al., 2008). This test can diagnose TB within four hours
f sampling by detecting anti-MA antibodies as immune surrogate
arkers for active disease even in HIV infected patients. Although
he use of the inhibition of binding of antibodies in a real-time
mmunoassay seemed to practically solve the problem of cross-
eactivity between MAs and cholesterol, it is expected that better
esolution between TB positive and TB negative patient sera will be
chieved if the nature of the cross-reactivity is better understood.
structure-activity investigation of the antigenicity of MAs and
holesterol may identify an individual synthetic MA which is more
electively antigenic than the natural mixtures.
MAs comprise a large number of various structures within and
mong Mycobacterium species and in a few other genera. In M.
uberculosis, they consist mainly of alpha-, keto- and methoxy-MA
ubclasses, each containing mixtures of homologues of vary-
ng chain length and, in some cases different stereochemistry
round the functional groups in the main (mero-) chain (Dobson
ig. 1. Structures of the prominent homologues of three main classes of MA of Mycobacter
rans-cyclopropane form of natural methoxy-mycolic acid.s of Lipids 163 (2010) 800–808 801
et al., 1985). They are present either bound to the cell wall as
penta-arabinose tetramycolates or as sugar esters (e.g., trehalose
dimycolates and trehalose monomycolates). There is increasing
evidence of the importance of some natural free MAs (Ojha et al.,
2008). Whether all, a few, or one of these MAs is detected as anti-
gens by TB patient antibodies is not clear and is one focus of this
report. Pan et al. (1999) indicated that the methyl esters of homol-
ogous mixtures of natural methoxy-MAs are more antigenic than
those of the keto-MA or the non-oxygenated alpha-MA. A more
sensitive and speciﬁc diagnostic assay could possibly be developed
by making use of speciﬁc stereoisomers of single chain lengths of
synthetic MA subclasses instead of using natural mixtures of MA.
Because different MA subclasses dominate in certain stages of the
growth of mycobacteria or stage of disease, it could also be that
a speciﬁc synthetic MA antigen could provide more reliable data,
reveal information on the progress of the disease and be better able
to distinguish between TB positive and TB negative patient sera.
The three major classes of MA are exempliﬁed by structures
A–C (Fig. 1). In each of these, the stereochemistry of the hydroxy
acid part is R,R- and that of the methoxy-methyl fragment in B
is reported to be S,S. The -methylketone of C is also apparently
of S-stereochemistry, although often in the isolation of such com-
pounds from cells by chemical hydrolysis this centre is epimerized
to a mixture of R- and S-forms. The absolute stereochemistry of the
cis-cyclopropane remains uncertain, although if a common inter-
mediate is involved in producing methoxy-, hydroxy-, keto- and
cyclopropane functionalities, it will be as shown in A–C (see e.g.,
Koza et al., 2009a).More recently it has become clear that hydroxy-
MAs are probably intermediate in the formation of methoxy- and
keto-MAs and indeed some examples have been detected directly
(Quémard et al., 1997; Dubnau et al., 1997). In a number of cases,
the proximal cis-cyclopropane is replaced by an -methyl-trans-
cyclopropane as in, for example, D. Generally such compounds
will be present together with the corresponding cis-cyclopropane
in the complex mixture of different classes and different homo-
logues (chain lengths) of MA extracted from cells. Even when
the MA extracted from cells is separated into -, methoxy- and
keto-classes, the cis- and trans-cyclopropanes are generally not
separated.
The chemical syntheses of MAs representative of various sub-
classes that appear in the cell wall of M.tb and containing both
cis-cyclopropanes and -methyl-trans-cyclopropanes have only
been reported since 2005 (Al Dulayymi et al., 2005, 2006a,b, 2007;
Koza andBaird, 2007;Koza et al., 2009b). Indeed, although there are
a number of reports on the biological effects of types ofMA isolated
from cells, we are unaware of any experiments which distinguish
the role of cis- and trans-cyclopropanes directly.
ium tuberculosis. A, alpha-; B, methoxy-; C, keto-mycolic acid; andD, the-methyl-
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The objectives of this study were: (i) to better understand
he cross-reactivity of MA antigens with cholesterol by select-
ng monoclonal antibody speciﬁcities from a recombinant chicken
mmunoglobulin gene library that might or might not cross-react
etween these two antigens and (ii) to determine the structural
eatures of MA required for antigenicity using TB positive and TB
egative pooled human serum samples in ELISA. This knowledge
ay be useful to improve TB serodiagnostic tests that are based on
he detection of antibodies to MAs as surrogate markers of active
B.
. Materials and methods
.1. Preparation of methyl ester of natural mycolic acid mixture
Mycolic acid from the M. tuberculosis virulent strain was pur-
hased from Sigma–Aldrich, batch M4537. The acid was converted
nto the corresponding methyl ester. MA (100mg to 0.1mmol) was
issolved in amixture of toluene:methanol (5:1, 18ml). Thereafter
2M solution in n-hexane of trimethylsilyldiazomethane (0.2ml,
.4mmol, 4mol eq.)was added. This additionwas repeated another
times, every 45min (0.1ml, 0.2mmol, 2mol eq.). The reaction
as monitored by TLC using 4:1 hexane:ethyl acetate solution.
fter stirring for 72h, the reaction was quenched by evapora-
ion of the volatiles to give a white residue. This was dissolved in
ichloromethane (15ml) and water (10ml) was added. The water
ayerwaswashedwith dichloromethane (2× 10ml). The combined
rganic layers were dried and the solvent evaporated to give the
esired MA methyl ester (me-MA). The HNMR and CNMR spectra
f this esterwere consistentwith those reported (Laval et al., 2001).
.2. Fluorescent labelling of natural mycolic acids
MAs (Sigma–Aldrich) were esteriﬁed to 5-bromomethyl-
uorescein (5BMF) as described by Lemmer et al. (2009).
.3. Preparation of synthetic mycolic acids
Mycolic acids representative of the major homologues present
n M.tb were prepared as previously described (Al Dulayymi et al.,
005, 2006a,b, 2007; Koza and Baird, 2007; Koza et al., 2009b)
r by simple variations of those methods. Full details of all the
nown compounds have been reported already; corresponding
etails for the unpublished isomers are provided as supplementary
nformation in Table 1.
.4. Generation of recombinant monoclonal scFv
.4.1. Phage display antibody library
A naive semi-synthetic chicken phage display library was used
VanWyngaardt et al., 2004). The library contains recombinant ﬁla-
entousbacteriophagesdisplaying scFvantibody fragments. These
ragments were derived from combinatorial pairings of chicken VH
nd VL immunoglobulin domains. VH and VL domains are linked
y an interpeptide segment consisting of the sequence (GGGGS)3,
nabling a fold typical of single variable fragments.
.4.2. Phage display antibody selection
A selection of the phages displaying MA reactive scFv’s
as conducted by several panning rounds. Maxisorp immuno-
ubes (Nunc-Immuno Tubes, Nunc, Denmark) were coated with
00g/ml mycolic acid (Sigma–Aldrich) dissolved in distilled hex-
ne, after which the hexane was allowed to evaporate at room
emperature. Coated immunotubeswerebrieﬂywashedwithphos-
hate buffered saline (PBS, pH 7.4), then blocked with 2% skimmed
ilk inphosphate buffered saline (2%MPBS) for 60min. Tubesweres of Lipids 163 (2010) 800–808
then exposed to 1012 transforming units of the phage library in 2%
MPBS, 0.1% Tween-20 buffer for 2h. Unbound phage was removed
by 10× washing with PBS containing 0.1% Tween-20 followed by
a further 10× wash with PBS to remove the Tween-20. Bound
phagewas elutedwith 100mM triethylamine and neutralizedwith
1M Tris, pH 7.4. For enrichment Escherichia coli TG1 was infected
with eluted phages, grown at 30 ◦C in 2× TYG broth (TY broth
supplemented with 2% glucose) containing 100g/ml ampicillin,
and rescuedwithM13-K07 helper phage (Invitrogen). Panningwas
repeated four times.
2.4.3. Screening of mycolic acid speciﬁc phage clones
Following theﬁnalpanning, individual ampicillin resistantE. coli
TG1 colonies were selected for further characterization. Colonies
were grown in 2× TYG broth supplemented with 100g/ml ampi-
cillin in 96-well Microtitre plates at 30 ◦C. Phages were rescued as
described previously (Van Wyngaardt et al., 2004). Phage clones
were screened by enzyme-linked immunosorbent assay (ELISA)
carried outwithMA coated (50g/ml)microtitre plates (Maxisorp,
Nunc, Denmark). Coating was done by adding 50l of 100g/ml
MA in hexane into each well and evaporating it overnight at room
temperature. Wells were brieﬂy washed with PBS, and blocked
with 300l of 2% MPBS for 60min. Phage containing supernatants
(25l) were mixed with blocking solution (25l), added to each
well, and incubated for 60min at 30 ◦C. Wells were washed three
times with PBS-0.1% Tween-20. Mouse monoclonal antibody B62-
FE2, speciﬁc forM13ﬁlamentousphage, in2%MPBS-0.1%Tween-20
(50l) was added to each well and further incubated for 60min
at 30 ◦C. Bound phages were detected using rabbit anti-mouse
IgG antibody conjugated with horseradish peroxidase (HRP). Sig-
nals were developed with 3,3′,5,5′-tetramethylbenzidine using the
1-stepUltra TMB ELISA substrate solution according to manufac-
turer’s instructions. Plates were read using a Multiskan Ascent
(Thermo Labsystems) plate reader at a wavelength of 450nm.
2.4.4. Production and puriﬁcation of mycolic acid reactive scFv
Selected anti-MA phage obtained from E. coli TG1 clones was
used to infect E. coli HB2151 to obtain soluble scFv. Single colonies
were grown to an OD600 of 0.9 in 2× TYG broth supplemented
with 100g/ml ampicillin at 37 ◦C. ScFv expression was induced
with isopropyl-d-thiogalactosidase (IPTG; 1mM) and the culture
further incubated at 30 ◦C overnight, in glucose free media. Solu-
ble scFv was extracted with 1× TES buffer from the periplasm as
previously described (Hugo et al., 2002). ScFv was further afﬁn-
ity puriﬁed using an anti c-myc tag mAb commercially denoted as
9E10 IgG. The columnwas prepared by immobilising 9E10 IgG onto
aminoLink Plus gel (Pierce) according to manufacturer’s instruc-
tions. Periplasmic extracts were applied and after washing with
PBS, bound scFv was eluted with 100mM triethylamine and neu-
tralised with 1M Tris, pH 7.4. Eluted scFv was dialyzed against 1×
PBS, pH 7.4 at a MW cut-off of 10kDa. Samples were concentrated
using a Macrosep® ultraﬁltration device (Pall life sciences, USA)
and protein concentrations determined with a BCA protein detec-
tion kit (Pierce, USA), according to the manufacturer’s instructions.
Puriﬁed scFv was stored at −20 ◦C until further use.
2.5. Enzyme-linked immunosorbent assay (ELISA)
2.5.1. Analysis of the methyl ester and free acid of mycolic acids
For coatings done in PBS, methyl MA (me-MA) or free MA(250g) was dissolved in 1× PBS (4ml, pH 7.4) and placed on the
heat block at 90 ◦C for 20min. One vial of 1× PBS (4ml) served
as control. The solutions were vortexed for 30 s before sonifying
for 2min using a Virsonic soniﬁer at output of 2. The warm solu-
tions were subsequently loaded onto the ELISA plates (50l per
Physics of Lipids 163 (2010) 800–808 803
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Fig. 2. Human patient antibody recognition of natural Mtb MAs (MA mix), methyl
ester of natural MA (me-MA) and natural MA ﬂuorescein ester (5BMF-MA, prepared
fromnaturalMAmixand5BMF (structure))measuredwithELISA. PooledTBpositiveM. Beukes et al. / Chemistry and
ell) and the presence of oily drops viewed under a light micro-
cope. The plateswere kept at 4 ◦C overnight in plastic bags. For the
oatings done using hexane as coating solution, the lipid samples
250g) were dissolved in hexane (4ml, distilled) and vortexed
or 30 s. One vial of hexane (4ml) served as control. Solutions were
oated using a Hamilton syringe (50l/well) and the liquid was
oaded in the centre of the wells. Lipid was visible as a circular
axy layer after 2h of evaporation of the hexane at room temper-
ture. The plates were then stored in plastic bags at 4 ◦C overnight.
he human sera used for analysis of the methyl ester and free MA
amples were a pooled TB positive patient serum and a pooled TB
egative patient serum at a 1:20 dilution of serum. The pooled TB
os sample was created by pooling the sera of six patients, three
B positive/HIV positive (TB pos/HIV pos) and three TBpositive/HIV
egative (TBpos/HIVneg) randomly selected froma collectionused
or another study (Schleicher et al., 2002) in which it was shown
hat HIV or its state of progression to AIDS did not affect bind-
ng activity of antibodies to natural mycolic acids. TB neg patients
ere hospitalized for medical conditions other than tuberculo-
is, but showed no evidence of active tuberculosis. For ELISA the
BS lipid coated plates were aspirated and then blocked with 0.5%
asein/PBS (400l/well), while the dry hexane coated plates were
irectly blocked with 0.5% Casein/PBS (400l/well). After 2h, the
locking buffer was aspirated and serum (1:20 dilution in 0.5%
asein/PBS, pH 7.4) was added to the plate (50l/well). After 1h of
erum incubation, the wells were washed three times with a Well
ash4 ELISA washer (Labsystems) and ﬂicked out before adding
hegoat anti-human ImmunoglobulinG (IgG)peroxidase conjugate
whole molecule) for 30min at room temperature. Subsequently,
lates were washed three times and ﬂicked out before adding the
PD substrate solution (50l/well). Absorbancies were measured
ith a SLT 340 ATC photometer at 450nm with a reference ﬁlter
t 690nm at 30min and 50min for hexane and PBS coated plates
espectively. Background binding of serum to PBS or hexane was
orrected for by subtracting each serum response to PBS or hex-
ne from the antibody binding values obtained to the coated lipid
ntigens. Statistical comparisons of ELISA results were performed
sing the student t-test at a conﬁdence level of 95%.
.5.2. Analysis of the synthetic mycolic acids
To coat the ELISA plates with the different synthetic mycolic
cids subclasses and the natural mycolic acids to which they were
ompared, the lipidsweredissolved inhexane (3g/50l) andvor-
exed 1min, heated (at ∼85 ◦C) for a minute and allowed to stand
t room temperature for 15min. Hexane coating as such served as
control. The ELISA plates were coated with the different mycolic
cids at 50l per well by application to the well using Hamilton
yringes. The lipids were visible as a waxy coating after 2h of evap-
ration at RT. Plates were stored in a plastic bag at 4 ◦C overnight.
LISAwas done as described in Section 2.5.1 Background binding of
he serum to the plate was corrected for by subtracting the average
inding signal of antibody to MA from that registered for the hex-
ne coatedwells. The results obtainedwere analysedby themaking
se of the Student’s t-test for statistical signiﬁcance.
.5.3. Characterization of scFv’s binding speciﬁcity of mycolic
cids by sandwich ELISA
Puriﬁed scFv’s were tested for their binding activity using a
andwich ELISA. Maxisorp immunoplates were coated with MA as
escribed above. Plates were blocked with 2% MPBS for 60min
t 30 ◦C followed by a brief washing step with PBS. ScFv sam-
les (25l) were mixed with 2% MPBS (25l), added to the
ells and incubated for 60min. Unbound scFv was removed by
× washing with PBS-0.1% Tween-20. Anti c-myc monoclonal
ntibody (AbD serotec, UK) conjugated with HPR was used to
etect boundscFv fragments. Signalsweredevelopedwith3,3′,5,5′-and pooled TB negative sera were tested on the MA antigen derivatives coated from
hexane. Inner bars within the MA mix bars indicate the signals when coating was
done from hot PBS instead of hexane. The error bars indicate the standard deviation.
The 2.5d rule was applied to remove outliers. n=min 14, max 16.
tetramethylbenzidine using the 1-stepUltra TMB ELISA substrate
solution according tomanufacturer’s instructions. Plateswere read
using a Multiskan Ascent (Thermo Labsystems) plate reader at a
wavelength of 450nm.
3. Results and discussion
3.1. Antibody recognition of natural mycolic acids and ester
derivatives thereof
The strongly hydrophobic nature of MA makes them insoluble
in water and water miscible organic solvents. Their recognition by
water soluble antibodies in diluted serum is therefore somewhat
enigmatic and requires proof that antibody binding is not due to
non-speciﬁc hydrophobic antibody adsorption to the MA coated
surface.
In Fig. 2, the speciﬁcity of interaction of TB positive and negative
sera with coated MA antigens is demonstrated. Hexane appears to
be the better antigen coating solution compared to hot PBS. TheMA
methyl-ester (me-MA) is not recognizedbyantibodies,whereas the
free MA (MA mix) is recognized by both TB pos and TB neg patient
sera, but more strongly with TB pos sera. This supports the hypoth-
esis that the ELISA antibody binding signal is due to recognition of
an antigen consisting of one or more MAs, in which the hydroxyl
group of the freeMA-carboxylic acid probably participates in inter-
or intramolecular stabilization of a speciﬁc antigen conformation.
When the MA is ﬂuoresceinated by esteriﬁcation of its carboxylic
acid, the antibody binding signal is not signiﬁcantly affected, possi-
bly due to the fact that ﬂuorescein substitutes a free carboxylic acid
group in close proximity to where the ﬂuorophore compromises
the free carboxylic acid ofmycolic acid by ligandation (Fig. 2). These
results corroborate those of Lemmer et al. (2009), who reported
similar results when MA and ﬂuoresceinated MA were presented
804 M. Beukes et al. / Chemistry and Physics of Lipids 163 (2010) 800–808
Fig. 3. Chicken scFv antibody fragment recognition of MA (4=MA mix) and choles-
terol (3 =CH)with ELISA. Three scFv speciﬁtieswere identiﬁed, whichwere denoted
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sub-type, i.e. the precise spatial arrangement of the functional
groups, also appeared to be important. The observation that the
oxygenated mycolic acids are more antigenic than the alpha-MA
conﬁrms a previous report by Pan et al. (1999), although they usednti-MA (black bars), Anti-CH (grey bars) and Cross rxtive (blank bars). MA and
holesterol antigenswere coated fromhexane,while results on hexane (1 =Hexane)
nd PBS (2 =PBS) sham coated wells are indicated as well. The error bars indicate
he standard deviation of four repeats.
n immobilized liposomes to patient sera in a surface plasmon
esonance biosensor.
.2. Monoclonal scFv antibody fragment recognition of mycolic
cid and cholesterol
The high antibody binding signal with human TB negative sera
gainst MA, here again shown in Fig. 2, was previously speculated
o be due at least in part to cross-reactivity of the antibodies with
holesterol (Schleicher et al., 2002), an idea that was later sup-
orted by showing that both MA and cholesterol were recognized
qually well by Amphotericin B in an evanescent ﬁeld biosensor
Benadie et al., 2008). The cross-reactivity could be due to a mix-
ure ofmonospeciﬁc anti-cholesterol and anti-MAantibodies in the
era, or due to a true cross-reactivity where a particular antibody
peciﬁcity could recognize both MA and cholesterol. It is known
hat all humans have anti-cholesterol antibodies in their blood cir-
ulation (Swartz et al., 1988), which may at least in part explain the
igh antibody activity to MAs in TB negative patients. To test what
echanisms are possible for the cross-reactivity, scFv fragments
xpressed from a chicken antibody gene library were screened for
peciﬁcbinders to cholesterol andMA.Chickens, similar tohumans,
xpress a specialized MA-presenting CD1 (chCD1-1) on their anti-
en presenting cell populations (Dvir et al., 2010). Three different
peciﬁcities were detected and worked up from the phage display
ystem into monovalent, monoclonal scFv fragments. The mono-
peciﬁc anti-cholesterol scFv was dubbed anti-CH, while two scFv
peciﬁcities were generated against MA: one monospeciﬁc (Anti-
A) and one cross-reactive with cholesterol (Cross rxtive). Fig. 3
hows the characterizationof these three scFv’swith ELISA. The fact
hat a single monoclonal, monovalent cross-reactive scFv could be
ound with binding afﬁnity against both cholesterol and MA cor-
oborates the conclusion reported by Benadie et al. (2008) that
holesterol and MA share some antigenic structural properties and
ay explain why TB negative sera recognize cholesterol as well as
hey doMA. On the other hand, the ﬁnding that an scFv againstMAs
ouldbe found that doesnot cross-reactwith cholesterol (Anti-MA)
nd vice versa (Anti-CH), means that anti-MA antibodies may be
nduced during tuberculosis that are not merely anti-cholesterol
ntibodies with increased binding activity. This provides a broader
erspective on why the results in Fig. 2 show higher antibody
inding activity with TB pos patient sera than with TB neg sera
s was shown before with larger numbers of human patient seraFig. 4. Comparable ELISA signals of pooled TB positive and TB negative sera to syn-
thetic methoxy-mycolic acids. The error bars indicate the standard deviation. The
2.5d rule was applied to remove outliers. n=min 14, max 16.
from the same collection (Schleicher et al., 2002; Thanyani et al.,
2008).
3.3. Antibody recognition of synthetic mycolic acids
MAs in M.tb contain an R,R--alkyl--hydroxy acid. The main
branch, known as the meromycolate moiety, contains two func-
tionalities at the so called distal and proximal positions (Sekanka
et al., 2007). The proximal position is usually either a cis- or an
alpha-methyl-trans-cyclopropane, while the distal functionality is
usually a cis-cyclopropane or one of several oxygenated functional
groups including -methyl-hydroxyl-, -methyl-methoxy- and -
methyl-keto-groups. MA derivatives were chemically synthesised
that were representative of four MA subclasses, namely methoxy-
MA,hydroxy-MA, keto-MAandalpha-MA(Table1). The responseof
pooled TB positive and TB negative patient sera towards the differ-
ent synthetic MAs was compared to that obtained towards natural
free MA and isolated natural alpha MA in ELISA. The importance of
the stereochemistry of themerochains ofMAs for antigenic activity
was studied by using different single stereoisomers of chemically
synthesised MAs as antigens. Hexane was used as solvent to coat
the plates with the MAs.
In general, synthetic methoxy-MA bound most strongly (Fig. 4),
followed in descending order by hydroxy-MA (Fig. 5), keto-MA
(Fig. 6) and alpha-MA (Fig. 7). The exact stereochemistry of eachFig. 5. ELISA antibody binding signals of pooled TB positive and TB negative sera to
synthetic hydroxymycolic acids. The error bars indicate the standard deviation. The
2.5d rule was applied to remove outliers. n=min 15, max 16.
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Table 1
Synthetic MA structures, names and numbers relating to results.
MA subtype No. Structure Source
Alpha 1 Al Dulayymi et al. (2005)
2 Prepared by the same methods as described in Al
Dulayymi et al. (2005), but using the reverse absolute
stereochemistry of the cyclopropane intermediates
Keto 3 Koza et al. (2009b)
4 Koza et al. (2009b)
5 Prepared from the corresponding protected ketone as in
Koza and Baird (2007) using the methods of hydrolysis
described in Koza et al. (2009b)
Methoxy 6 Al Dulayymi et al. (2007)
7 Al Dulayymi et al. (2007)
8 Al Dulayymi et al. (2007)
9 Prepared using the same methods as described for the
three stereoisomers above (Al Dulayymi et al., 2007)
10 As for structure 5
Hydroxy 11 Koza et al. (2009b)
12 Koza et al. (2009b)
13 As for structure 5
14 As for structure 5
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eto-mycolic acids. The error bars indicate the standard deviation. The 2.5d rulewas
pplied to remove outliers. n=min 15, max 16.
hemethyl esters of theMA subclasses in ELISA, a result which con-
rasts our ﬁnding that the methyl esters are not antigenic (Fig. 2).
he packing of mycolic acids in a Langmuir monolayer has previ-
usly been shown to differ between alpha-, keto- andmethoxy-MA
ubclasses. Keto-MA tended more towards a W-shaped conﬁgura-
ion with exceptional rigidity in monolayers, whereas methoxy-
ndalpha-MAexhibitedamoreﬂexible conformation towardsvari-
tion of experimental parameters (Villeneuve et al., 2005, 2007).
hus, the packing of MA is inﬂuenced by the orientation of the
unctional groups that induce different conformations for inter-
ction with antibodies in sera. We propose that the antibody
inding to mycolic acids with TB negative sera is most likely due
o the presence of anti-cholesterol antibodies, known to exist in all
umans (Bıro et al., 2007; Swartz et al., 1988) that cross-react with
A.
Antibody binding to the natural MA mixture, as well as several
f the synthetic MAs was observed with both TB positive and TB
egative patient sera, while some synthetic MAs appeared to have
ittle or no antigenic activity. Although TB positive sera generally
ave better binding to the antigenic MAs than TB negative sera, no
ingle antigenic MA was signiﬁcantly better able to differentiate
etween TB positive and TB negative sera than the natural mixture
f MAs could. This could in principle mean that the synthetic MAs
ested were antigenic primarily to the antibodies that respond to
oth MA and cholesterol. The fact that TB positive patient sera sta-
istically score higher than TB negative patient sera in recognition
f MA in ELISA could then explained simply by a higher concentra-
ig. 7. ELISA antibody binding signals of TB positive and TB negative sera to syn-
hetic alpha mycolic acids. MA-mix= the natural mixture of mycolic acids, 13,
4 = chemically synthetic alpha MA with structures indicated. The error bars indi-
ate the standard deviation. The 2.5d rule was applied to remove outliers. n=min
, max 16.s of Lipids 163 (2010) 800–808
tion or afﬁnity of the anti-MA/cholesterol antibodies in TB patient
sera, even though monospeciﬁc antibody activity to mycolic acids
has been found to exist at least in the germ-line antibody gene
repertoire of chickens (Fig. 3).
The synthetic methoxy-MA subclass had the highest binding
to the antibodies of the four synthetic subclasses tested, followed
by hydroxy-, keto- and alpha-MA (Figs. 4–7). The stereochemistry
of the methoxy group and the cyclopropane is important for the
recognition by antibodies in the sera. Even small changes in the
stereochemical arrangement of the groups inﬂuenced the amount
of binding observed. As seen fromFig. 4, the antibodybinding signal
of R,R-methoxy-methyl-cis-cyclopropane MA conﬁguration (No. 8)
most closely resembles the response towards the natural mixture
of MA. A change of the conﬁguration of either the cis-cyclopropane
(No. 7), or the methoxy-methyl-fragment to S,S (No. 9) reduced
the binding signal by approximately half. If the more weakly anti-
genic S,R-cis conﬁguration of the cyclopropane is combined with
the S,S-methoxy conﬁguration (No. 6), the signal is once again
halved, even though the S,S-methoxy conﬁguration is the reported
stereochemistry in natural compounds (Al Dulayymi et al., 2007).
However, when the cyclopropane group assumed the methyl-
trans-conﬁguration as in structureNo. 10, in this case in association
with the reported natural S,S conﬁguration around the methoxy-
methyl fragment, an antigenicity signalwas obtained thatwas even
higher than that obtained for thenaturalMAmixture (P<0.01). This
shows beyond doubt that the stereochemical conﬁguration of the
two functional groups on themero-chain of themethoxy-MA inﬂu-
ences theway inwhich they are recognised by antibodies in human
serum. It remains to be determined whether other combinations of
absolute conﬁguration of the methoxy-methyl fragment and the
methyl-trans-cyclopropane will provide an even more antigenic
MA.
The synthetic hydroxy-MAs (Fig. 5), which are the likely precur-
sors of both methoxy- and keto-MA (Yuan and Barry, 1996; Yuan
et al., 1997; Asselineau et al., 2002) all attracted weaker antibody
binding compared to the natural MA mixture. The methyl-trans
conﬁguration of the proximal cyclopropane group appears to be a
pre-requisite for antigenicity of the hydroxy-MAs (Nos.13 and 14,
compared to Nos. 11 and 12, Fig. 5). The hydroxy-methyl fragment
in the R,R conformation (No. 14) is more antigenic than the sup-
posednatural S,S conﬁguration (No. 13)with statistical signiﬁcance,
P<0.01, as was found with the methoxy group stereochemistry
(Fig. 4).
Like the hydroxy-MAs, keto-MAs also require a proximal cyclo-
propane in the methyl-trans-cyclopropane conﬁguration (No. 5,
Fig. 6) to be antigenic, compared to the two cis-cyclopropane
conﬁgurations (Nos. 4 and 3, Fig. 6) that did not show any sig-
niﬁcant antigenic activity. In these cases, a mixture of epimers
at the chiral centre adjacent to the keto-group was tested; it is
possible that R and S-isomers show different antigenicity. Thus in
all the oxygenated MAs (i.e., methoxy-, hydroxy- and keto-MA),
the methyl-trans-cyclopropane conﬁguration provides for the best
antigenic functionality.
Two synthetic alpha MAs (Fig. 7, Nos.1 and 2) were compared
to the natural MA mix to determine their relative antigenicity. The
antibody binding signal to the synthetic alpha MA failed to distin-
guish between TB pos and TB neg patient sera compared to the
natural MA mix. The synthetic MA gave such low antibody bind-
ing signals, that nothing could be learned from the variations in
the stereochemistries of the distal and proximal cyclopropanes on
the antigenicity of alpha-MA. Itmust be noted that the stereochem-
istry of cis-cyclopropanes in alpha-mycolates remains to be proven.
However, if a common synthetic intermediate is involved in the
production of the different functionalities and this is the same for
both proximal and distal substituents, the natural stereochemistry
will be as in 1.
Physic
4
o
c
i
m
e
m
i
t
i
t
e
f
a
w
i
r
m
2
i
b
t
ﬁ
p
m
a
n
c
t
c
f
o
t
c
a
r
a
t
o
r
I
t
c
a
t
t
a
d
a
m
t
c
b
s
M
t
p
i
l
t
eM. Beukes et al. / Chemistry and
. Conclusion
MAs have been shown to play an important role in the virulence
f tuberculousmycobacteria.Notonlydo theyact aspathogenasso-
iated molecular patterns (PAMP) for induction of murine innate
mmunity (Korf et al., 2005), but they are also able to reprogramme
urinemacrophages tomodulate their inﬂammatory activity (Korf
t al., 2006). That these responses towards free MA administration
aybe related to the functional groupsexpressedon themerochain
s inferred by ﬁndings such as that mutants of M. tuberculosis
hat have no oxygenated mycolic acids are of reduced virulence
n mice (Dubnau et al., 2000), that mutants without the ability to
rans-cyclopropanate their oxygenatedMAs are hypervirulent (Rao
t al., 2006), and that the trehalose dimycolate (TDM) extracted
rom such trans-cyclopropanase mutants stimulates inﬂammatory
ctivity of murine macrophages, compared to TDM extracted from
ild-type M. tuberculosis. Experiments like these are not feasible
n humans, but the importance of MAs in human tuberculosis was
ecently demonstrated by implicating patient serum antibodies to
ycolic acids as surrogate markers of active TB (Thanyani et al.,
008) using biosensor technology. With biosensor technology the
nterference of cross-reactive antibodies against cholesterol could
e avoided that was encountered with the more standard ELISA
echnology (Schleicher et al., 2002). Here we determined that the
ne structure of MAs is important for recognition by human TB
atient serum antibodies.
First, we showed that methyl esters of the natural mycolate
ixture showed no antigenicity, but that it was maintained by
ddition of a ﬂuorescein to the MA carboxylate that substituted a
ew carboxylic acid functional group close to the ester bond of the
onjugate. This suggested that MA assumes an antigenic conﬁgura-
ion that is stabilized by hydrogen bonding to the (undissociated)
arboxylic acid.
Two different scFv monoclonal antibody fragments generated
roma chicken antibody gene library that recognizedMAs, ofwhich
ne cross-reacted with cholesterol and the other not, indicated
hat the cross-reactivity of human patient serumbetweenMAs and
holesterol could either be due to a mixture of anti-cholesterol and
nti-MA antibodies and/or due to a single antibody with cross-
eactive speciﬁcity, or both. It also proves that anti-cholesterol
ntibodies do not necessarily cross-react with MA. Analysis of
he antigenicity of a range of synthetic MA suggested that the
xygenated mycolic acids were most antigenic. Methoxy-MA rep-
esented the strongest antigen for both TB pos and TB neg patient.
mportant, however,was thegeneral observation that the two func-
ional groups on the merochain of single synthetic MAs were both
ritically important to determine antigenicity for human serum
ntibody recognition.
The results seem to favour methoxy MA of M. tuberculosis as
he strongest functional entity or antigen to use in TB serodiagnos-
ic devices. A proximal methyl-trans-cyclopropane enhances the
ntigenicity of these functionalities. The R,R-conﬁguration of the
istalmethoxy group still remains to be tested in combinationwith
trans-cyclopropane proximal group to determine antigenicity in
ethoxy-MA. The results do not necessarily provide information as
o the stereochemistry of the naturally produced MAs found in the
ellwalls ofM. tb, as the antibody recognitionof natural classesmay
e due to the complex mixtures of homologues and cyclopropane
tereochemistries present. The best antigenicity seen in synthetic
A does not therefore necessarily indicate the most likely struc-
ure of the MA antigen(s) in nature. Thus, it seems unlikely that a
articular MA molecule can constitute an antibody binding site ﬁll-
ng antigen or hapten. Rather, the surface created by packed MAs is
ikely to be the structure that is recognized by antibodies, similar to
he case of monoclonal antibody recognition of cholesterol (Kruth
t al., 2001). Unlike cholesterol, which has a deﬁned structure, MAs of Lipids 163 (2010) 800–808 807
exists as amixture inM. tuberculosis. It maywell be thatMA folding
and packing is inﬂuenced by the presence of different types of sub-
classes and variants thereof, such that the natural MA antigen(s)
may never be recreated synthetically by the use of a single species
of pure synthetic MA. It was a disappointment that the cholesterol
cross-reactivity couldnotbedeﬁned toaparticular classofMA from
the antigenic mixture as implied by the observation that the TB
positive andTBnegative serawerenotbetter resolvedwithanypar-
ticular antigenic MA structure. Nevertheless, the demonstration of
biological antigenic activity of individual stereochemically unique
chemically syntheticMAs to levels that approximateor evenexceed
the antigenic activity of the natural mixture of MAs puriﬁed from
M. tuberculosis bodes well for the possibilities towards improving
the existing assays that aim at detection of anti-MA antibodies as
surrogate markers for TB disease (Schleicher et al., 2002; Thanyani
et al., 2008; Lemmer et al., 2009; Mathebula et al., 2009). It allows
for the ﬁrst time the possibility of providing exact speciﬁcations
for an optimal antigen coated surface and the covalent linkage of
MA to sensor surfaces for easy regeneration and engineering of the
antigen to deﬁne the best window of antibody afﬁnity and speci-
ﬁcity.
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